AlloVir (Nasdaq: ALVR) has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics.
The all-stock transaction will result in AlloVir acquiring all outstanding equity in Kalaris, with AlloVir shareholders retaining a 25% stake in the combined company, and Kalaris shareholders taking the remaining 75%.
The newly merged entity, expected to operate as Kalaris Therapeutics, will trade under the Nasdaq ticker “KLRS.” The combined company will begin with approximately $100 million in cash, anticipated to support operations through the fourth quarter of 2026.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze